论文部分内容阅读
用MRI(magnetic resonance imaging)技术探索连接抗人精子蛋白17单克隆抗体(anti-Sp17 mAb)的磁性纳米探针对体外培养及动物体内Sp17+卵巢癌的靶向性。将anti-Sp17mAb连接到表面包覆壳聚糖的超顺磁性氧化铁纳米颗粒上,制成磁性纳米探针anti-Sp17-MNP,用作MRI阴性对比剂。将磁性纳米探针与Sp17+和Sp17-培养的肿瘤细胞共育,进行一系列体外磁共振成像实验。荷瘤小鼠尾静脉注射磁性纳米颗粒,用7T磁共振仪在体成像,观察肿瘤部位的信号变化,并用普鲁士蓝染色肿瘤组织切片,观察有无铁粒子聚集。体外MRI数据显示,anti-Sp17-MNP与细胞靶向结合,并与细胞共育2 h后,Sp17+HO-8910的T2*信号强度比Sp17-HepG2低2倍;anti-Sp17-MNP对肿瘤细胞的靶向作用可被重组人Sp17阻断。7T磁共振仪对动物在体肿瘤成像结果显示,感兴趣区因磁性纳米探针靶向聚集而导致信号降低,并经组织切片普鲁士蓝染色证实。本研究结果表明,用anti-Sp17抗体和新的合成路线制备的纳米探针具有用作MR对比剂进行分子成像的潜能。
Magnetic resonance imaging (MIR) was used to explore the targeting of Sp17 + ovarian cancer cells in vitro and in vivo by magnetic nano-probes linked with anti-Sp17 mAb. Anti-Sp17mAb was attached to superparamagnetic iron oxide nanoparticles coated with chitosan to form magnetic nanoparticle probe anti-Sp17-MNP, which was used as MRI negative contrast agent. The magnetic nano-probes were co-cultured with Sp17 + and Sp17-cultured tumor cells for a series of in vitro magnetic resonance imaging experiments. Tumor-bearing mice were injected with magnetic nanoparticles through the tail vein, and the signal was observed on the tumor site with a 7T magnetic resonance instrument. The tumor tissue sections were stained with Prussian blue to observe the presence or absence of iron particle aggregation. In vitro MRI data showed that T2 * signal intensity of Sp17 + HO-8910 was 2-fold lower than that of Sp17-HepG2 when anti-Sp17-MNP was targeted to cells and incubated with cells for 2 h. Anti-Sp17- Targeting of cells can be blocked by recombinant human Sp17. 7T magnetic resonance imaging of animals in vivo imaging showed that the region of interest due to magnetic nano-probe targeted aggregation led to reduced signal, and confirmed by tissue sections Prussian blue staining. The results of this study show that the nano-probes prepared with the anti-Sp17 antibody and a new synthetic route have the potential to be used as MR contrast agents for molecular imaging.